Organogenesis Holdings Inc.: Business Overview, Financials & Competitive Analysis
Organogenesis Holdings Inc. scores 5/10 on the AskCyborg Cyborg Score (Mixed). Near-term CMS-driven market disruption masks strong operational execution and transformational growth potential from ReNu if approved. Strong Q4 2025 results with record revenue and substantial YoY growth demonstrate operational strength. However, the company expects full-year 2026 total net revenue to decline 25% to 38% year-over-year due to clinician confusion.
What is Organogenesis Holdings Inc.'s industry? Organogenesis Holdings Inc. (organogenesis.com) operates in Regenerative Medicine / Advanced Wound Care / Biotech Medical Devices. AskCyborg classifies Organogenesis Holdings Inc. under Regenerative Medicine / Advanced Wound Care / Biotech Medical Devices in its company registry.
Organogenesis is a regenerative medicine company that develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. The company reporte...
Cyborg Score thesis
Near-term CMS-driven market disruption masks strong operational execution and transformational growth potential from ReNu if...
Read the full analyst-debate transcript →Get the Latest Organogenesis Holdings Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeOrganogenesis Holdings Inc. Overview
Pro stress-test →Organogenesis is a regenerative medicine company that develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. The company reported record Q4 2025 net product revenue of $225.1 million (up 78% YoY) with advanced wound care sales up 83%. However, recent CMS policy changes have created near-term market disruption affecting 2026 performance.
Strategic Profile
Pro stress-test →The company's product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. CMS shifted reimbursement to support high-quality, evidence-backed PMA products while reducing payment for non-PMA products, which is favorable to Organogenesis' portfolio. The company initiated a rolling BLA submission for ReNu late last year and expects to complete it in the first half of 2026, describing it as a potential transformational opportunity if approved by the FDA for knee osteoarthritis pain.
Competitive Landscape
Pro stress-test →Upcoming CMS reimbursement and LCD changes position Organogenesis with significant market share and margin advantage over competitors due to its portfolio strength. The company operates in regenerative medicine and advanced wound care, competing with various biotech and medical device firms focused on tissue engineering and wound healing solutions.
Industry Context
Organogenesis Holdings Inc. operates in Regenerative Medicine / Advanced Wound Care / Biotech Medical Devices.
Key facts
Founded: 1985 · Headquarters: Canton, Massachusetts · Employees: 854 · Revenue: $225.6M (Q4 2025) · Market cap: $0.413B